| Literature DB >> 23006411 |
Suleen S Ho1, Satvinder S Dhaliwal, Andrew P Hills, Sebely Pal.
Abstract
BACKGROUND: Evidence suggests that exercise training improves CVD risk factors. However, it is unclear whether health benefits are limited to aerobic training or if other exercise modalities such as resistance training or a combination are as effective or more effective in the overweight and obese. The aim of this study is to investigate whether 12 weeks of moderate-intensity aerobic, resistance, or combined exercise training would induce and sustain improvements in cardiovascular risk profile, weight and fat loss in overweight and obese adults compared to no exercise.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23006411 PMCID: PMC3487794 DOI: 10.1186/1471-2458-12-704
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Participant flow chart.
Participant characteristics at baseline
| Male/Female | 1/15 | 3/12 | 3/13 | 3/14 |
| Age (years) | 52 ± 1.8 | 55 ± 1.2 | 52 ± 1.1 | 53 ± 1.3 |
| | (40 – 66) | (44 – 62) | (43 – 59) | (43 – 64) |
| Weight (kg) | 85.1 ± 4.2 | 91.9 ± 4.1 | 89.3 ± 4.5 | 90 ± 4 |
| | (64.8 – 123) | (65.9 – 124.1) | (71.9 – 127.5) | (62.2 – 122.3) |
| Body Mass Index (kg/m2) | 32.4 ± 1.4 | 32.7 ± 1.3 | 33 ± 1.3 | 33.3 ± 1.2 |
| | (26 – 48) | (25 – 45.6) | (25.8 – 44.6) | (23.4 – 40.2) |
| Body Fat % (DXA) | 46.5 ± 1.7 | 44.6 ± 1.9 | 43.7 ± 1.3 | 45.8 ± 1.6 |
| | (35.9 – 59.9) | (30.7 – 52.5) | (34.6 – 52.2) | (28.8 – 55.5) |
| Waist Circumference (cm) | 100.3 ± 3.6 | 103.7 ± 2.6 | 104 ± 3.2 | 102.2 ± 3.2 |
| | (80 – 131) | (82 – 118) | (83.5 – 135.5) | (81.5 – 124.5) |
| Waist: Hip Ratio | 0.85 ± 0.02 | 0.87 ± 0.02 | 0.88 ± 0.02 | 0.86 ± 0.02 |
| | (0.75 – 1.01) | (0.76 – 1) | (0.78 – 1.03) | (0.74 – 1.02) |
| Fasting Triglyceride (mmol/L) | 1.25 ± 0.17 | 1.36 ± 0.19 | 1.27 ± 0.12 | 1.1 ± 0.1 |
| | (0.48 – 2.6) | (0.62 – 3.01) | (0.51 – 2.14) | (0.48 – 1.91) |
| Fasting Total Cholesterol (mmol/L) | 5.51 ± 0.29 | 5.83 ± 0.32 | 5.49 ± 0.38 | 5.71 ± 0.31 |
| | (2.59 – 7.12) | (3.58 – 7.87) | (2.92 – 8.95) | (3.74 – 9.2) |
| Fasting HDL Cholesterol (mmol/L) | 1.42 ± 0.11 | 1.38 ± 0.09 | 1.34 ± 0.08 | 1.43 ± 0.11 |
| | (0.9 – 2.28) | (0.91 – 1.99) | (0.91 – 2.19) | (0.71 – 2.08) |
| Fasting LDL Cholesterol (mmol/L) | 3.51 ± 0.26 | 3.89 ± 0.3 | 3.56 ± 0.33 | 3.78 ± 0.27 |
| | (1.42 – 5.26) | (2.08 – 6.06) | (1.58 – 7.02) | (2.4 – 6.88) |
| Fasting Glucose (mmol/L) | 5.35 ± 0.13 | 5.68 ± 0.17 | 5.81 ± 0.46 | 5.38 ± 0.13 |
| | (4.55 – 6.22) | (4.39 – 7.11) | (4.91 – 7.17) | (4.2 – 6.46) |
| HOMA2-IR | 1.92 ± 0.28 | 1.72 ± 0.52 | 1.86 ± 0.18 | 1.86 ± 0.13 |
| | (1 – 4.7) | (0.9 – 2.5) | (0.7 – 3.5) | (1.2 – 2.8) |
| NEFA (mmol/L) | 0.51 ± 0.03 | 0.5 ± 0.04 | 0.49 ± 0.04 | 0.46 ± 0.03 |
| (0.3 – 0.79) | (0.17 – 0.87) | (0.18 – 0.94) | (0.29 – 0.7) |
Values are mean ± SEM and (range) for n = 64 participants at baseline. BIA: bioelectrical impedance analysis. DXA: dual-energy x-ray absorptiometry. HOMA2-IR: homeostasis model assessment of insulin resistance. NEFA: non-esterified fatty acid.
Changes in nutritional variables
| | | | |
| Control | 7085.1 ± 550.8 | 7535.6 ± 1197.8 | 6723.2 ± 585.9 |
| Aerobic | 8741.6 ± 1052.7 | 7471.7 ± 706.7 | 7179.4 ± 502.3* |
| Resistance | 7776.6 ± 418.0 | 7234.5 ± 478.0 | 6937.1 ± 471.6* |
| Combination | 7675.3 ± 324.8 | 7726.5 ± 428.6 | 6920.2 ± 402.7 |
| | | | |
| Control | 41.8 ± 3.0 | 42.1 ± 1.8 | 40.7 ± 2.5 |
| Aerobic | 42.5 ± 3.1 | 44.4 ± 2.6 | 41.2 ± 2.3 |
| Resistance | 40.2 ± 1.6 | 41.7 ± 1.9 | 39.4 ± 2.0 |
| Combination | 44.2 ± 1.9 | 44.8 ± 1.9 | 43.4 ± 1.9 |
| | | | |
| Control | 18.9 ± 1.5 | 20.1 ± 1.1 | 18.5 ± 1.2 |
| Aerobic | 18.3 ± 1.3 | 19.7 ± 1.4 | 20.8 ± 1.4* |
| Resistance | 19.8 ± 1.1 | 19.0 ± 0.7 | 20.2 ± 1.0 |
| Combination | 19.1 ± 0.9 | 18.5 ± 1.0 | 18.4 ± 1.1 |
| | | | |
| Control | 33.5 ± 2.2 | 34.0 ± 1.5 | 37.1 ± 1.8 |
| Aerobic | 35.2 ± 2.6 | 33.1 ± 1.9 | 35.1 ± 1.8 |
| Resistance | 36.0 ± 1.2 | 34.8 ± 1.8 | 36.4 ± 1.4 |
| Combination | 33.9 ± 1.7 | 35.7 ± 1.7 | 35.7 ± 1.4 |
| | | | |
| Control | 41.6 ± 2.1 | 40.2 ± 1.5 | 43.6 ± 2.1 |
| Aerobic | 41.6 ± 2.3 | 41.8 ± 1.6 | 42.5 ± 1.9 |
| Resistance | 40.4 ± 1.8 | 43.3 ± 1.8 | 42.6 ± 1.0 |
| Combination | 45.4 ± 1.6 | 45.5 ± 1.6 | 42.8 ± 3.0 |
| | | | |
| Control | 40.6 ± 1.4 | 41.4 ± 1.1 | 39.6 ± 1.3 |
| Aerobic | 41.3 ± 1.5 | 39.6 ± 0.8 | 38.8 ± 1.2 |
| Resistance | 39.9 ± 0.9 | 40.3 ± 1.0 | 40.8 ± 1.2 |
| Combination | 38.9 ± 1.0 | 39.5 ± 1.0 | 39.5 ± 1.1 |
| | | | |
| Control | 17.7 ± 1.5 | 18.4 ± 1.1 | 16.9 ± 1.4 |
| Aerobic | 17.1 ± 1.2 | 18.4 ± 1.6 | 18.6 ± 1.8 |
| Resistance | 19.6 ± 1.5 | 16.6 ± 1.2 | 16.8 ± 1.1 |
| Combination | 15.9 ± 1.0 | 15.2 ± 0.8 | 17.5 ± 2.4 |
Values are daily mean ± SEM (n = 53) of the nutritional data recorded in 3-day food diaries at baseline, week 8 and week 12. Statistical significance from baseline is indicated by * p < 0.05. SFA: saturated fatty acid. MUFA: monounsaturated fatty acid. PUFA: polyunsaturated fatty acid.
Figure 2Comparison of changes from baseline between groups for body weight (A), BMI (B), body fat (C), body fat % (D) and android fat % (E). Body fat was measured by DXA. Data represents mean ± SEM. Statistical differences between groups indicated by different superscripts, p < 0.05.
Changes in body measurements and cardio-respiratory fitness
| Control | 85.1 ± 4.2 | 85.5 ± 4.3 | 85.1 ± 4.3 |
| Aerobic | 91.9 ± 4.1 | 91.1 ± 4.1 | 91.0 ± 4.0 |
| Resistance | 89.3 ± 4.5 | 89.3 ± 4.3 | 89.2 ± 4.4 |
| Combination | 90.0 ± 4.0 | 88.8 ± 3.6* | 88.4 ± 3.6* |
| | | | |
| Control | 32.4 ± 1.4 | 32.5 ± 1.5 | 32.4 ± 1.5 |
| Aerobic | 32.7 ± 1.3 | 32.5 ± 1.3 | 32.4 ± 1.2 |
| Resistance | 33.0 ± 1.3 | 33.1 ± 1.3 | 33.0 ± 1.3 |
| Combination | 33.3 ±1.2 | 33.0 ± 1.1* | 32.8 ± 1.1* |
| | | | |
| Control | 37.1 ± 2.3 | | 37.3 ± 2.4 |
| Aerobic | 39.3 ± 2.5 | | 38.6 ± 2.5 |
| Resistance | 37.6 ± 2.3 | | 37.2 ± 2.4 |
| Combination | 39.3 ± 1.8 | | 37.7 ± 1.8* |
| | | | |
| Control | 46.5 ± 1.7 | | 46.7 ± 1.8 |
| Aerobic | 44.6 ± 1.9 | | 44.1 ± 1.8 |
| Resistance | 43.7 ± 1.3 | | 43.2 ± 1.4 |
| Combination | 45.8 ± 1.6 | | 44.8 ± 1.8* |
| | | | |
| Control | 51.5 ± 1.8 | | 51.7 ± 1.8 |
| Aerobic | 50.7 ± 1.6 | | 50.4 ± 1.9 |
| Resistance | 49.2 ± 1.3 | | 49.3 ± 1.3 |
| Combination | 52.2 ± 1.4 | | 50.9 ± 1.4* |
| | | | |
| Control | 100.3 ± 3.6 | 98.3 ± 3.7* | 99.1 ±3.6 |
| Aerobic | 103.7 ± 2.6 | 102.5 ± 2.6 | 101.6 ± 2.9* |
| Resistance | 104.0 ± 3.2 | 102.4 ± 3.2 | 101.4 ± 3.3* |
| Combination | 102.2 ± 3.2 | 100.5 ± 2.8 | 99.6 ± 3.0* |
| | | | |
| Control | 27.2 ± 1.4 | | 24.9 ± 0.8 |
| Aerobic | 24.8 ± 1.1 | | 26.2 ± 0.9 |
| Resistance | 24.8 ± 1.8 | | 26.8 ± 0.8 |
| Combination | 26.5 ± 1.3 | 28.2 ± 0.8* |
Values are mean ± SEM (n=64) at baseline, week 8 and week 12. Statistical significance from baseline is indicated by * p < 0.05.
Changes in fasting blood measurements, resting energy expenditure and respiratory quotient
| | | | |
| Control | 1.25 ± 0.17 | 1.37 ± 0.19 | 1.48 ± 0.23 |
| Aerobic | 1.36 ± 0.19 | 1.29 ± 0.11 | 1.40 ± 0.16 |
| Resistance | 1.27 ± 0.12 | 1.21 ± 0.16 | 1.38 ± 0.18 |
| Combination | 1.10 ± 0.10 | 1.08 ± 0.10 | 1.36 ± 0.17* |
| | | | |
| Control | 5.51 ± 0.29 | 5.88 ± 0.32 | 5.49 ± 0.28a |
| Aerobic | 5.83 ± 0.32 | 5.72 ± 0.29 | 5.56 ± 0.37a |
| Resistance | 5.49 ± 0.38 | 5.76 ± 0.36 | 6.15 ± 0.44* b |
| Combination | 5.71 ± 0.31 | 5.74 ± 0.27 | 5.75 ± 0.26ab |
| | | | |
| Control | 1.42 ± 0.11 | 1.45 ± 0.11ab | 1.35 ± 0.10a |
| Aerobic | 1.38 ± 0.09 | 1.31 ± 0.08a | 1.28 ± 0.07* a |
| Resistance | 1.34 ± 0.08 | 1.44 ± 0.08b | 1.44 ± 0.08* b |
| Combination | 1.43 ± 0.11 | 1.44 ± 0.10ab | 1.41 ± 0.11ab |
| | | | |
| Control | 3.51 ± 0.26 | 3.79 ± 0.31 | 3.47 ± 0.25a |
| Aerobic | 3.89 ± 0.30 | 3.82 ± 0.27 | 3.64 ± 0.33a |
| Resistance | 3.56 ± 0.33 | 3.76 ± 0.31 | 4.08 ± 0.36* b |
| Combination | 3.78 ± 0.27 | 3.80 ± 0.22 | 3.71 ± 0.22a |
| | | | |
| Control | 0.51 ± 0.03 | 0.45 ± 0.04a | 0.48 ± 0.03 |
| Aerobic | 0.50 ± 0.04 | 0.59 ± 0.05b | 0.47 ± 0.04 |
| Resistance | 0.49 ± 0.04 | 0.52 ± 0.04ab | 0.54 ± 0.05 |
| Combination | 0.46 ± 0.03 | 0.49 ± 0.03ab | 0.54 ± 0.04 |
| | | | |
| Control | 5.35 ± 0.13 | 5.46 ± 0.10 | 5.26 ± 0.18 |
| Aerobic | 5.68 ± 0.17 | 5.78 ± 0.18 | 5.73 ± 0.10 |
| Resistance | 5.81 ± 0.46 | 5.81 ± 0.17 | 5.77 ± 0.16 |
| Combination | 5.38 ± 0.13 | 5.31 ± 0.10 | 5.55 ± 0.13 |
| | | | |
| Control | 14.89 ± 2.29 | 14.82 ± 1.66 | 14.76 ± 1.69 |
| Aerobic | 13.05 ± 1.01 | 16.67 ± 1.48* | 15.87 ± 1.86 |
| Resistance | 13.98 ± 1.40 | 16.82 ± 1.33* | 13.48 ± 1.24 |
| Combination | 14.24 ± 1.03 | 17.07 ± 1.33* | 14.25 ± 1.25 |
| | | | |
| Control | 6.75 ± 0.74 | 6.23 ± 0.58 | 7.08 ± 0.77a |
| Aerobic | 5.68 ± 0.59 | 5.57 ± 0.78 | 5.58 ± 0.77ab |
| Resistance | 5.92 ± 1.05 | 4.54 ± 0.64 | 4.46 ± 0.45* b |
| Combination | 5.30 ± 0.56 | 5.33 ± 0.82 | 5.04 ± 0.78ab |
| | | | |
| Control | 6088.4 ± 392.7 | | 6081.9 ± 384.8 |
| Aerobic | 6388.2 ± 281.2 | | 6283.5 ± 264.6 |
| Resistance | 6468.3 ± 312.1 | | 6431.2 ± 302.5 |
| Combination | 6328.2 ± 319.7 | | 6252.1 ± 291.1 |
| | | | |
| Control | 0.84 ± 0.007 | | 0.84 ± 0.012 |
| Aerobic | 0.84 ± 0.010 | | 0.84 ± 0.014 |
| Resistance | 0.85 ± 0.016 | | 0.81 ± 0.016* |
| Combination | 0.83 ± 0.023 | 0.84 ± 0.017 |
Values are mean ± SEM (n = 64) of fasting blood measurements at baseline, week 8 and week 12. Statistical significance from baseline (within groups) is indicated by * p < 0.05. Statistical differences between groups at week 8 or 12 with baseline as a covariate indicated by different superscripts p < 0.05. TG: triglyceride. TC: total cholesterol. HDL: high density lipoprotein. LDL: low density lipoprotein. NEFA: non-esterified fatty acid. ApoB48: apolipoprotein B48. REE: resting energy expenditure. RQ: respiratory quotient.
Figure 3Comparison of changes from baseline between groups for cardio-respiratory fitness. Values are mean ± SEM (n = 64). Statistical differences between groups indicated by different superscripts, p < 0.05.